Drug-oozing implant to control addiction approved in U.S.
A heroin addict holds a used syringe in his teeth after shooting up in an abandoned lot in San Juan, Friday, July 31, 2009. (AP Photo / Brennan Linsley)
Matthew Perrone, The Associated Press
Published Thursday, May 26, 2016 3:58PM EDT
Last Updated Thursday, May 26, 2016 6:24PM EDT
WASHINGTON -- Federal health officials on Thursday approved an innovative new option for Americans struggling with addiction to heroin and painkillers: a drug-oozing implant that curbs craving and withdrawal symptoms for six months at a time.
The first-of-a-kind device, Probuphine, arrives as communities across the U.S. grapple with a wave of addiction tied to opioids, highly-addictive drugs that include legal pain medications like OxyContin and illegal narcotics like heroin. Roughly 2.5 million Americans suffer from addiction disorders related to the drugs, according to federal estimates.
The implant from Braeburn Pharmaceuticals is essentially a new, long-term delivery system for an established drug, buprenorphine, which has long been used to treat opioid addiction. But its implantable format could help patients avoid dangerous relapses that can occur if they miss a medication dose.
The matchstick-size implant slowly releases a low dose of buprenorphine over six months. Previously the drug was only available as a pill or film that dissolves under the tongue. It is considered a safer, more palatable alternative to methadone, the decades-old standard for controlling opioid addiction.
Probuphine is intended for patients who have already been stabilized on low-to-medium doses of buprenorphine for at least a half year. Braeburn estimates that one fourth, or 325,000, of the 1.3 million patients currently taking buprenorphine meet that criterion.
The FDA previously rejected Probuphine in 2012, judging the drug's dose was too low to reliably help the broad range of opioid-addicted patients. Braeburn and partner Titan Pharmaceuticals resubmitted the product with additional data and it received a positive endorsement from federal advisers earlier this year.
The FDA said Thursday that Probuphine should be used as part of a multipronged addiction treatment program that includes counselling and other forms of support. Doctors who implant the device must also receive special training to safely insert and remove the device.
FDA officials are spotlighting new treatment options for opioid abuse, after weathering heavy criticism for not acting faster to combat the epidemic of addiction and overdose tied to the drugs.
"We must do everything we can to make new, innovative treatment options available that can help patients regain control over their lives," said Dr. Robert Califf, who became FDA commissioner in February.
Heroin and opioid painkillers caused 28,650 fatal overdoses in 2014, the highest number on record in the U.S. Despite those numbers, experts say buprenorphine remains underused due to federal limits on how many prescriptions each doctors can write, gaps in insurance and a lack of acceptance by doctors.
Along with increasing compliance, Probuphine has the potential to address other problems associated with the oral buprenorphine, including illegal diversion and accidental poisoning in children.
The implant comes with significant safety risks, including nerve damage and punctured skin if it accidentally moves after implantation. Patients should be seen during the first week after the procedure and at least once a month afterward for counselling and follow-up care.
Braeburn's CEO Behshad Sheldon says 2,200 doctors have already signed up to take the training course required to administer Probuphine. The company could train as many as 4,000 physicians by the end of the year, she says.